NOF CORPORATION
4403・Prime Market・Chemicals
NOF CORPORATION4403
NOF CORPORATION4403
Reference Indicators
Market Cap
6,476¥100M
P/E (Forecast)
16.1x
P/B
2.1x
Dividend Yield (Forecast)
2.56%
ROE
14.1%
EV/EBITDA
8.1x
Financial Summary
Unit: ¥M
| Item | 2022Mar 2022 | 2023Mar 2023 | 2024Mar 2024 | 2025Mar 2025 | 2026Mar 2026 |
|---|---|---|---|---|---|
Net Sales | 192,642 | 217,709 | 222,252 | 238,310 | 257,967 |
Cost of Sales | 123,713 | 141,766 | 142,762 | 153,156 | 168,874 |
Gross Profit | 68,928 | 75,943 | 79,490 | 85,153 | 89,092 |
SG&A Expenses | 33,333 | 35,318 | 37,348 | 39,845 | 41,681 |
Operating Income | 35,595 | 40,624 | 42,142 | 45,308 | 47,411 |
Non-operating Income | 2,543 | 2,973 | 4,018 | 2,426 | 3,753 |
Non-operating Expenses | 514 | 415 | 582 | 1,162 | 797 |
Ordinary Income | 37,624 | 43,183 | 45,577 | 46,572 | 50,366 |
Extraordinary Income | 1,218 | 4,882 | 3,025 | 4,340 | 8,839 |
Extraordinary Losses | 864 | 25 | 134 | 133 | 1,876 |
Pre-tax Income | 37,977 | 48,040 | 48,468 | 50,778 | 57,329 |
Income Taxes | 11,255 | 14,025 | 14,407 | 14,173 | 16,671 |
Net Income | 26,690 | 33,973 | 33,990 | 36,497 | 40,550 |
EBITDA | 41,504 | 46,983 | 49,081 | 53,273 | 69,527 |
Gross Margin | 35.8% | 34.9% | 35.8% | 35.7% | 34.5% |
Operating Margin | 18.5% | 18.7% | 19.0% | 19.0% | 18.4% |
ROA | 9.2% | 11.0% | 10.0% | 10.2% | 10.2% |
ROE | 12.6% | 14.8% | 13.5% | 13.4% | 14.1% |
Segment Performance
Unit: ¥M
2026
| Segment | Net Sales | Operating Income | Operating Margin |
|---|---|---|---|
| 機能化学品事業 | 145,751 | 26,846 | 18.4% |
| 医薬・医療・健康事業 | 49,931 | 15,816 | 31.7% |
| 化薬事業 | 61,675 | 7,979 | 12.9% |
| その他 | 608 | 434 | 71.4% |